Eva Renee Barnett Sells 4,747 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett sold 4,747 shares of the firm’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a total value of $133,200.82. Following the completion of the sale, the chief financial officer now owns 350,667 shares in the company, valued at $9,839,716.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eva Renee Barnett also recently made the following trade(s):

• On Wednesday, May 22nd, Eva Renee Barnett sold 4,042 shares of Immunovant stock. The stock was sold at an average price of $29.65, for a total transaction of $119,845.30.
• On Wednesday, April 17th, Eva Renee Barnett sold 12,253 shares of Immunovant stock. The stock was sold at an average price of $29.06, for a total value of $356,072.18.

Immunovant Stock Up 2.2 %

IMVT stock traded up $0.65 during mid-day trading on Wednesday, reaching $30.35. 1,037,272 shares of the stock traded hands, compared to its average volume of 1,197,848. The business has a 50-day moving average of $27.75 and a two-hundred day moving average of $32.61. Immunovant, Inc. has a 52 week low of $18.82 and a 52 week high of $45.58.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). During the same quarter in the previous year, the company posted ($0.46) earnings per share. As a group, equities research analysts anticipate that Immunovant, Inc. will post -2.11 EPS for the current year.

Analyst Ratings Changes

IMVT has been the topic of a number of recent analyst reports. Oppenheimer cut their price target on shares of Immunovant from $50.00 to $46.00 and set an “outperform” rating on the stock in a report on Monday, June 3rd. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target on shares of Immunovant in a research note on Monday, March 25th. HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Immunovant in a report on Thursday, May 30th. The Goldman Sachs Group started coverage on Immunovant in a report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research note on Tuesday, June 18th. Seventeen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $48.75.

Institutional Investors Weigh In On Immunovant

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP acquired a new position in Immunovant during the 3rd quarter valued at $6,473,000. Citigroup Inc. raised its position in shares of Immunovant by 43.3% during the third quarter. Citigroup Inc. now owns 126,316 shares of the company’s stock valued at $4,849,000 after buying an additional 38,179 shares during the last quarter. Vanguard Group Inc. increased its stake in Immunovant by 14.0% in the third quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock valued at $239,290,000 after acquiring an additional 764,530 shares during the period. Legato Capital Management LLC boosted its holdings in Immunovant by 74.7% during the fourth quarter. Legato Capital Management LLC now owns 11,840 shares of the company’s stock valued at $499,000 after purchasing an additional 5,061 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its position in shares of Immunovant by 11.2% during the 4th quarter. CoreCap Advisors LLC now owns 6,407 shares of the company’s stock worth $270,000 after buying an additional 647 shares during the period. 47.08% of the stock is owned by institutional investors.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.